Journal Information
Vol. 36. Issue 7.
Pages 377-380 (July - August 2000)
Share
Share
Download PDF
More article options
Vol. 36. Issue 7.
Pages 377-380 (July - August 2000)
Full text access
Asociación de bupropión y parches de nicotina como terapia para dejar de fumar
Combining nicotine patches and bupropion in smoking cessation therapy
Visits
4777
I. Sampablo Lauroa,
Corresponding author
isl01b@nacom.es

Correspondencia: Servicio de Aparato Respiratorio. Hospital de Sant Boi. Buenaventura Calopa, 13. 08830 Sant Boi de Llobregat. Barcelona.
, L. Loresa, F. Collb, P. Rebasaa
a Servicio de Neumología. Hospital de Sant Boi. Barcelona
b Servicio de Aparato Respiratorio. Instituto Universitario Dexeus. Barcelona
This item has received
Article information

El abandono del consumo de tabaco es una medida terapéutica de primer orden para todos los pacientes afectados de bronconeumopatías. A lo largo del tiempo, van apareciendo diferentes estrategias para ayudar a nuestros pacientes a dejar su hábito tabáquico. El bupropión es un fármaco que fue desarrollado inicialmente como agente antidepresivo; recientemente se ha descrito la acción por la cual aumenta la capacidad del fumador de abstenerse de fumar.

Estudio descriptivo que valora a un grupo de 86 pacientes que voluntariamente quiso someterse a un programa de deshabituación tabáquica utilizando como tratamiento 300 mg de bupropión durante 4 semanas, asociado a los parches de nicotina, dosis decrecientes cada 4 semanas, durante 12 semanas. Los resultados obtenidos fueron que un 69% de nuestros pacientes consiguió abstenerse de fumar después de 6 meses de seguimiento, sin describirse efectos secundarios significativos. Este porcentaje disminuyó al 58,6% al cabo de un año de seguimiento. Al analizar si existía alguna relación entre el número de veces que el paciente había intentado previamente dejar de fumar y el éxito en este intento, no se observaron diferencias significativas. Tampoco se encontraron al valorar si existía enfermedad pulmonar concomitante y abandono tabáquico.

Concluimos afirmando que la asociación de bupropión y nicotina transdérmica es una buena alternativa para ayudar a nuestros pacientes a dejar de fumar.

Palabras clave:
Bupropión
Parche de nicotina
Deshabituación tabáquica

Smoking cessation is a first-line treatment for patients with bronchial and pulmonary diseases. Various strategies have been developed to help patients quit. Bupropion, a drug initially developed as an antidepressant, has recently been shown to have effects that increase the ability of a smoker to quit.

This descriptive study, enrolling 86 patients who volunteered for a smoking cessation program, assesses the use of 300 mg of bupropion over a 4-week period combined with 12 weeks of nicotine patch application at doses that were lowered every 4 weeks. Abstinence was achieved by 69% of patients after 6 months of follow-up and no significant side effects were described. The percentage decreased to 58.6% after one year of follow-up. No significant differences were found between success in quitting in this study and either the number of prior attempts to quit or concomitant respiratory disease.

We conclude that bupropion combined with transdermal nicotine is a good option to aid patients to achieve smoking cessation.

Key words:
Bupropion
Nicotine patch
Smoking cessation
Full text is only aviable in PDF
Bibliografía
[1.]
U.S. Department of Health, Education and Welfare. The health benefits of smoking cessation: a report of the Surgeon General U.S. Department of Health and Human Services, Public Health Service. CDC Center for Chronic Disease Prevention and Health Promotion. Office on Smoking and Health. D.H.H.S. Publicación n.o (C.D.C.) 8416, 1990.
[2.]
U.S. Department of Health and Human Services. The Health consequences of involuntary smoking. A report of the Surgeon General U.S. Department of Health and Human Services, Public Health Service. C.D.C. D.H.H.S. Publicación n.o (C.D.C.) 87-8.398, 1986.
[3.]
J. To.
Tabaco y cáncer: de la asociación epidemiológica a la evidencia molecular.
Med Clin (Barc), 112 (1999), pp. 589-594
[4.]
Estudio de los estilos de vida de la población adulta española.
Ministerio de Sanidad y Consumo.
Dirección General de Salud Pública, (1992),
[5.]
Departament de Sanitat i Seguretat Social, (DSSS)..
Enquesta de Salut de Catalunya.
Servei Català de Salut, SCS, DSSS, (1995),
[6.]
L. Lores, E. Monsó, A. Rosell, I. Badorrey, I. Sampablo Lauro.
¿Nos mienten los enfermos controlados en un dispensario de neumología respecto a su hábito tabáquico?.
Arch Bronconeumol, 35 (1999), pp. 219-222
[7.]
G.A. Giovino, D.M. Shelton, M.W. Schooley.
Trend in cigarette smoking cessation in the United States.
Tobacco Control, 2 (1993), pp. 3-16
[8.]
Smoking, Health.
A physician responsibility. A statement of the Joint Committee on Smoking and Health.
Eur Respir J, 8 (1995), pp. 808-811
[9.]
N.L. Benowitz.
Pharmacological aspects of cigarettes smoking and nicotine addiction.
N Engl J Med, 319 (1988), pp. 1318-1330
[10.]
R.D. Hurt, D. Sachs, E. Glover, K.P. Offord, et al.
A comparison of sustained release bupropion and placebo for smoking cessation.
N Engl J Med, 337 (1997), pp. 1195-1202
[11.]
J. Prochazcka, C. Diclemente.
Stages and processes of self change of smoking: toward and integrative model of change.
J Consult Clin Psychology, 51 (1983), pp. 390-395
[12.]
C. Orleans, L. George, J. Houpt.
Health promotion in primary care: a survey of U.S. family practitioners.
Prevent Med, 14 (1985), pp. 636-647
[13.]
J.K. Ockene.
Physician-delivered interventions for smoking cessation: strategies for increasing effectiveness.
Prevent Med, 16 (1987), pp. 723-737
[14.]
C.A. Jiménez, K.O. Fagerström.
Reducción del consumo de tabaco. ¿Una estrategia para dejar de fumar?.
Arch Bronconeumol, 35 (1999), pp. 229-232
[15.]
P. Tonnesen, V. Fryd, M. Hansen, J. Helsted, A. Gunnersen, M. Forchammer, et al.
Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking.
N Engl J Med, 318 (1988), pp. 15-18
[16.]
Transdermal Nicotine Study Group.
Transdermal nicotine for smoking cessation: six month results from two multicenter controlled clinical trials.
JAMA, 266 (1991), pp. 3133-3138
[17.]
R.F. Snyder, F.O. Davis, J.E. Henningfield.
The tobacco withdrawal syndrome Performance decrements assessed on a computerized test battery\.
Drug Alcohol Depend, 23 (1989), pp. 259-266
[18.]
S. Kato, Y. Wakasa, T. Yanagita.
Relationship between minimum reinforcing doses and injection speed in cocaine and pentobarbital self administration in crabeating monkeys.
Pharmacol Biochm Behav, 28 (1987), pp. 407-410
[19.]
E.R. Gritz.
Patterns of puffing in cigarette smokers.
Self-administration of abused substances: methods for study (NIDA Research Monograph 20), National Institute on Drug Abuse, (1978), pp. 221-235
[20.]
L.S. Covey, A.H. Glassman, F. Stetner.
Depression and depressive symptoms in smoking cessation.
Compr Psychiatry, 31 (1990), pp. 350-354
[21.]
L.H. Ferry, R.J. Burchette.
Efficacy of bupropion for smoking cessation in non-depressed smokers.
J Addict Dis, 13 (1994), pp. 249
[22.]
D.E. Jorenby, S.J. Leischow, M. Nides, S. Rennard, et al.
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
N Engl J Med, 340 (1999), pp. 685-691
[23.]
P. Tonnesen, P. Paoletti, G. Gustavsson, M. Russell, et al.
Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial.
Eur Respir J, 13 (1999), pp. 238-246
[24.]
T. Glynn, M. Manley.
How to help your patients stop smoking National Cancer Institute Manual for Physicians (N.I.H. publicación n.o 90-3064).
Bethesda, (1989),
[25.]
Prochazcka J, Diclemente CC. Stages of change in the modification of problems behaviors. En: Hersen M, Eisler R, Miller P, editores. Progress in behaviors modification. Newbury Park, California:
[26.]
J. Prochazcka, W. Velicer, C.C. Diclemente.
Predicting change in smoking status for self changers.
Addict Behav, 10 (1985), pp. 395-406
Copyright © 2000. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?